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Inflammation, infections and coagulation share pathways, mechanisms and markers 
in the blood. Evidence first came from more basic science and experimental studies 
and later also from clinical epidemiological studies. In chapter 2 we provided an 
overview of studies on infections and inflammatory diseases that reported an 
absolute or relative risk of venous thrombosis by a systematic review of the 
literature of the last 15 years. Infections in general, and more specific human 
immunodeficiency virus (HIV), pneumonia and urinary tract infections appear to 
increase the risk of venous thrombosis about 2-fold. During more severe or acute 
episodes of an infectious disease, this risk might even be higher. Patients with 
inflammatory diseases, like inflammatory bowel disease or ANCA-associated 
vasculitis, were also found to be at a 2 to 4-fold increased risk of subsequent venous 
thrombosis. During active disease or flare-ups, the risk of venous thrombosis 
reached a 8-fold increase.  
 To determine whether self-reported, mild symptoms of inflammation or 
infection of common (and probably viral) origin could also be a risk factor for 
venous thrombosis, we performed the Beast study. In this case-control study of 
consecutive patients suspected of venous thrombosis, who visited the emergency 
department of our university medical center, we found a 2.5-fold increased risk of 
venous thrombosis for self-reported inflammatory or infectious symptoms, as 
described in chapter 3. Interaction with CRP was also found, and the risk of venous 
thrombosis was highest in patients with elevated CRP levels and a positive history of 
inflammatory or infectious symptoms, pointing towards an at least partial causative 
association for CRP with venous thrombosis (1). However, due to our study design 
(a case-control study with retrospectively collection of data), questions about 
causality could not be proven but only made likely.  
 In chapter 4 we reported on 5 patients (2%) from the BEAST case-control 
study with an active cytomegalovirus infection and venous thrombosis. Because we 
did not find any patient with an active infection without venous thrombosis, we 
could not calculate a relative risk of venous thrombosis. Remarkably, all patients 
were female and below 37 years of age, with another known (non-genetic) risk 
factor and at least a mildly elevated factor VIII:C. That all these 5 subject were 
women, might be explained by the fact that they are at higher risk of venous 
thrombosis due to oral contraception use and being in the reproductive part of their 
live. Also, women may be more exposed to cytomegalovirus than men, as has been 
observed in other population based studies (2).  
 Another frequently reported disease probably associated with venous 
thrombosis is HIV. After introduction of combined anti-retroviral therapy (cART), 
not only the disease but also the remedy appeared to be related with an increased 
risk of venous and arterial thrombosis. In chapter 5 we performed a review of the 
literature to determine the risk of venous and arterial thrombosis in HIV-infected 
patients, as well as to determine the contribution of HIV itself and the therapy to 
this risk. Both HIV and cART appear to contribute to an increased procoagulant 
state and thus an increased risk of arterial and venous thrombosis. HIV-patients are 
at a 4-6 fold increased risk of venous or arterial thrombosis. Although these patients 
have an increased risk of venous or arterial thrombosis, this does not outweigh the 
benefits of anti-retroviral therapy, as shown by the remarkably increased survival of 
these patients during the anti-retroviral era.  
 Chapter 6 shows the data of a cohort of 104 patients with HIV-infection, 
treated at our outpatient clinic. In these patients, we determined whether active 
cytomegalovirus infection could add to the risk of venous thrombosis by disturbing 
the hemostasis of coagulation even more, compared to HIV-infection alone. As 
cytomegalovirus infection is more often found in patients with a more prgressive 
stage of HIV-disease, it might be that HIV-stage alone could account for the 
procoagulant changes. In this cross-sectional study, active cytomegalovirus 
infection was associated with hypercoagulability independently of the stage of HIV 
disease. Most prominent features of this were significant higher levels of FVIII:C and 
fibrinogen.  
 In the final part of this thesis we described a number of studies on markers of 
inflammation or coagulation, the risk of venous thrombosis according to these 
markers and the influence of the acute phase reaction on the relationship between 
them. First, in chapter 7, the association between elevated glucose levels and 
venous thrombosis was determined, using the BEAST case-control study. Although 
hyperglycemia and coagulation have been earlier described together, whether this 
indeed would be associated with an increased risk of venous thrombosis was only 
recently investigated in one epidemiological study (3). They reported a 2.2-fold 
increased risk of venous thrombosis in patients with hyperglycemia and in the 
highest quartile of the distribution of glucose levels compared to the lowest 
quartile, independent of manifest diabetes mellitus. However, adjustment for the 
acute phase reaction (which could be a confounder in the association between 
hyperglycemia and venous thrombosis) could not be done. The authors also asked 
for replication of their study. Therefore, we performed this analysis in the BEAST 
case-control study, showing that patients with hyperglycemia indeed had an 
increased risk of unprovoked first venous thrombosis, comparing the highest 
quartile to the lowest quartile of glucose (OR 5.2, 95%CI, 1.2-23.4). This association 
was at least partially influenced by the acute phase reaction, as after adjustment for 
CRP the odds ratio declined to 3.0 (95%CI, 0.4-22.9). Overall, hyperglycemia 
appears to be associated with an increased risk of venous thrombosis, also in the 
acute phase, but a conclusion about causality cannot be drawn due to the study 
design of these two studies, where blood samples were taken shortly after the event 
took place.  
 Hereditary decreased free protein S levels are associated with an increased 
risk of venous thrombosis, especially when these levels are very low (4, 5). In 
chapter 8 we tried to replicate our previous finding (5) of the low cut-off value of 
<41 IU/dL for decreased free protein S levels as a risk factor for venous thrombosis, 
using blood that was sampled in the acute phase. If this can reliably be detected in 
the acute phase, i.e. when patients present at the emergency department, one could 
determine thrombophilic defects immediately when needed and thereby estimate 
the risk of recurrence of venous thrombosis without delay. We found a CRP-
adjusted 1.9-fold increased risk of venous thrombosis for patients with a free 
protein S below 41 IU/dL in the acute setting using the BEAST case-control study. 
The association between free protein S and venous thrombosis was not 
independent of the acute phase reaction. Second, we found that total complement 
4 binding protein (C4BP) levels had no influence on this association. In the acute 
phase, C4BP levels increase and as C4bP binds to protein S, it is hypothesized that in 
this way it might be accountable for the decrease of free protein S levels in the acute 
phase.  
 Although viewed by some as an acute phase protein (6, 7), FVIII:C and the risk 
of (recurrent) venous thrombosis is supposed to be independent of the acute phase 
(8-10). However, the designs used in some studies were insufficient to determine 
the real relationship between the acute phase and FVIII:C. In chapter 9 we described 
the follow-up of FVIII:C, CRP and fibrinogen levels in 75 patients from the BEAST 
case-control study. These patients were followed from baseline until end of 
treatment (on average 6 to 12 months later). We concluded that the acute phase 
reaction indeed influenced FVIII:C levels, but that most patients who had an 
elevated FVIII:C level at baseline, kept a persistent elevated FVIII:C level during and 
at the end of treatment (75%). However, the absolute value declined somewhat 
because of fading of the acute phase (207 to 175 IU/dL, p for trend 0.003). Our 
second observation was that those patients with a persistent elevated FVIII:C had 
only mild elevated CRP levels at baseline, compared to higher CRP levels in the 
patients with an initially elevated FVIII:C levels and a normal FVIII:C level at the end 
of treatment. In this way, patients with a high risk of recurrent venous thrombosis 
because of a persistent elevated FVIII:C might be detected as early as at the start of 
treatment of their first venous thrombosis.  
 Finally, in chapter 10 we showed that rivaroxaban, a new oral anti factor Xa 
antagonist, interferes in vitro with the one-stage FVIII:C clotting assay. We 
hypothesized that this interference could be based on a new, unknown, 
anticoagulant or anti-inflammatory effect of rivaroxaban, mainly in-vivo.  
However, it appeared that the effect is caused by the direct blockage of newly 
formed factor Xa in vitro, i.e. while the test is being performed. Applying high 
dilutions could only partially diminish this effect. The chromogenic assay we used 
was also influenced by rivaroxaban, because factor X has to be activated during this 
test, which is thus also factor Xa dependent. Clinicians have to be aware that new 
anticoagulants, including rivaroxaban, can interfere with coagulation tests, such as 
the one-stage FVIII:C clotting assay.  
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